ストックスクリーナーアプリを入手
3.59
6.02%
-0.23
前日終値:
$3.82
開ける：
$3.84
24時間の取引高:
459.96K
Relative Volume:
0.56
時価総額：
$229.07M
収益：
-
当期純損益:
$-36.95M
株価収益率:
-4.2738
EPS:
-0.84
ネットキャッシュフロー:
$-33.46M
1週間 パフォーマンス:
-9.57%
1か月 パフォーマンス:
-9.34%
6か月 パフォーマンス:
-53.07%
1年 パフォーマンス:
-42.10%
1日の値動き範囲:
$3.59
$3.8899
1週間の範囲:
$3.535
$4.24
52週間の値動き範囲:
$3.01
$13.68
Larimar Therapeutics Inc Stock (LRMR) Company Profile
名前
Larimar Therapeutics Inc
セクター
電話
844-511-9056
住所
THREE BALA PLAZA EAST. SUITE 506, BALA CYNWYD, PA
LRMR を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
LRMR
Larimar Therapeutics Inc
|
3.59 | 229.07M | 0 | -36.95M | -33.46M | -0.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Larimar Therapeutics Inc Stock (LRMR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-01-29 | 開始されました | Truist | Buy |
| 2024-10-16 | 開始されました | Oppenheimer | Outperform |
| 2024-10-03 | 開始されました | Wedbush | Outperform |
| 2024-10-02 | 開始されました | H.C. Wainwright | Buy |
| 2024-09-04 | 開始されました | Robert W. Baird | Outperform |
| 2024-04-03 | 開始されました | Leerink Partners | Outperform |
| 2023-11-17 | アップグレード | Citigroup | Neutral → Buy |
| 2022-10-19 | 開始されました | Guggenheim | Buy |
| 2022-02-15 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2021-02-10 | 開始されました | JMP Securities | Mkt Outperform |
| 2021-02-01 | 開始されました | William Blair | Outperform |
すべてを表示
Larimar Therapeutics Inc (LRMR) 最新ニュース
BlackRock, Inc. Increases Stake in Larimar Therapeutics Inc - GuruFocus.com
Insider’s View: Deciphering Larimar Therapeutics Inc (LRMR)’s Financial Health Through Ratios - The Dwinnex
Larimar Therapeutics Inc (LRMR)’s stock chart: A technical perspective - US Post News
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Receives $20.13 Average Price Target from Brokerages - MarketBeat
Larimar Therapeutics (NASDAQ:LRMR) Coverage Initiated at Truist Financial - MarketBeat
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Shares Bought by JPMorgan Chase & Co. - Defense World
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Receives Average Rating of “Buy” from Analysts - Defense World
Truist Financial Initiates Coverage on Larimar Therapeutics (NASDAQ:LRMR) - Defense World
Larimar started at buy by Truist on Friedreich's ataxia drug - MSN
Truist Initiates Larimar Therapeutics at Buy With $18 Price Target -January 29, 2025 at 06:37 am EST - Marketscreener.com
Truist Securities Initiates Coverage of Larimar Therapeutics (LRMR) with Buy Recommendation - MSN
Larimar Therapeutics Aligns Executive Incentives with Milestones - MSN
Larimar Therapeutics awards key executives performance-based stock By Investing.com - Investing.com Australia
Larimar Therapeutics awards key executives performance-based stock - MSN
Larimar Therapeutics' SWOT analysis: stock potential hinges on FA treatment - MSN
JMP Securities maintains $21 target on Larimar Therapeutics stock - MSN
Larimar Therapeutics (NASDAQ:LRMR) Earns “Buy” Rating from HC Wainwright - Defense World
Larimar Therapeutics Initiates Dosing in Pediatric Study for Friedreich’s Ataxia - MSN
Larimar Therapeutics' SWOT analysis: stock potential hinges on FA treatment By Investing.com - Investing.com Australia
Assenagon Asset Management S.A. Sells 6,488 Shares of Larimar Therapeutics, Inc. (NASDAQ:LRMR) - Defense World
Larimar Therapeutics’ SWOT analysis: stock potential hinges on FA treatment By Investing.com - Investing.com Nigeria
Larimar Therapeutics' (LRMR) Buy Rating Reiterated at HC Wainwright - MarketBeat
Larimar Therapeutics, Inc. Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreich's Ataxia - Marketscreener.com
Larimar Therapeutics Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreich's Ataxia - The Manila Times
Larimar Therapeutics Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreich’s Ataxia - Business Upturn
Larimar Therapeutics Begins Pediatric Dosing of Nomlabofusp for Friedreich's Ataxia Treatment - StockTitan
Larimar Therapeutics Shares Promising Data on Nomlabofusp at Ataxia Research Congress - MSN
Barclays PLC Buys 45,781 Shares of Larimar Therapeutics, Inc. (NASDAQ:LRMR) - Defense World
JANUS HENDERSON GROUP PLC Acquires Additional Shares in Larimar Therapeutics Inc - GuruFocus.com
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Brokerages Set Larimar Therapeutics, Inc. (NASDAQ:LRMR) PT at $20.43 - MarketBeat
Bullish Larimar Therapeutics Insiders Loaded Up On US$522.0k Of Stock - Yahoo Finance
Geode Capital Management LLC Decreases Stake in Larimar Therapeutics, Inc. (NASDAQ:LRMR) - Defense World
Geode Capital Management LLC Has $5.90 Million Stock Holdings in Larimar Therapeutics, Inc. (NASDAQ:LRMR) - MarketBeat
Barclays PLC Acquires 45,781 Shares of Larimar Therapeutics, Inc. (NASDAQ:LRMR) - Defense World
Larimar Therapeutics: Positive Friedreich's Ataxia Data Can Only Get Better (NASDAQ:LRMR) - Seeking Alpha
Jane Street Group LLC Acquires 50,622 Shares of Larimar Therapeutics, Inc. (NASDAQ:LRMR) - Defense World
Franklin Resources Inc. Acquires 3,549 Shares of Larimar Therapeutics, Inc. (NASDAQ:LRMR) - Defense World
Why Is Larimar Therapeutics Stock Trading Lower On Monday? - AOL
XTX Topco Ltd Buys New Shares in Larimar Therapeutics, Inc. (NASDAQ:LRMR) - Defense World
What is HC Wainwright’s Forecast for LRMR FY2025 Earnings? - Defense World
William Blair Has Negative Estimate for LRMR Q1 Earnings - Defense World
FY2025 Earnings Estimate for LRMR Issued By HC Wainwright - MarketBeat
William Blair Has Pessimistic Outlook of LRMR Q1 Earnings - MarketBeat
Charles Schwab Investment Management Inc. Lowers Stake in Larimar Therapeutics, Inc. (NASDAQ:LRMR) - Defense World
Larimar Therapeutics Reports Promising Results for Friedreich’s Ataxia Treatment - MyChesCo
Larimar Therapeutics Inc (LRMR) 財務データ
収益
当期純利益
現金流量
EPS
0.82%
0.53%
大文字化:
|
ボリューム (24 時間):